PharmaSat

PharmaSat. It was a pioneering NASA biological research nanosatellite designed to investigate the effects of microgravity on yeast antifungal resistance. Developed at the Ames Research Center, this 3-unit CubeSat successfully conducted autonomous, in-orbit experiments to determine if microbial organisms alter their gene expression and metabolic processes in space. The mission demonstrated the feasibility of using low-cost, small satellites for sophisticated life science investigations, paving the way for future astrobioogy studies on larger platforms.

Overview

The spacecraft was part of a broader initiative by NASA to utilize the standardized CubeSat form factor for cost-effective scientific missions. Built around a 3U bus, it carried a self-contained, automated microfluidic laboratory system capable of culturing and monitoring microorganisms. This project was managed by the Small Spacecraft Technology Program at Ames Research Center, leveraging expertise from the NASA Engineering and Safety Center. Its development involved collaboration with academic partners like Santa Clara University and industry contributors such as Jet Propulsion Laboratory.

Mission and objectives

The primary objective was to study how the antifungal agent fluconazole affects the growth of the yeast Saccharomyces cerevisiae in the microgravity environment of low Earth orbit. Scientists sought to understand if the stress response and drug efficacy observed in terrestrial laboratories were altered in space, which has implications for astronaut health during long-duration missions. A key goal was to validate autonomous experiment protocols, including precise fluid handling and optical monitoring, without intervention from ground controllers at Goddard Space Flight Center.

Scientific payload

The core payload was the Microfluidic Biochip system, a miniaturized laboratory that contained three independent experiment modules. Each module housed a growth chamber pre-loaded with yeast cells and nutrients, with the ability to inject precise doses of fluconazole after an initial growth period. An integrated optical density sensor, using light-emitting diodes and photodetectors, measured cell growth by tracking culture turbidity. The system's microprocessor executed a pre-programmed sequence, controlling pumps, valves, and sensors while logging data for later transmission via the satellite's S-band radio.

Launch and operations

It launched on 19 May 2009 as a secondary payload aboard a Minotaur I rocket from the Mid-Atlantic Regional Spaceport at Wallops Flight Facility. The primary payload was the TacSat-3 satellite for the Department of Defense. After deployment from the PolySat CP6 carrier, the satellite's systems were activated, and it began transmitting telemetry to the ground station network. The autonomous experiment commenced shortly after achieving a stable orbit, with data downlinked to the Mission Control Center at Ames Research Center over the following weeks.

Results and legacy

The mission successfully demonstrated that yeast cells exhibited altered growth patterns and reduced susceptibility to fluconazole under microgravity conditions, providing crucial data for pharmacology in space. All systems, including the fluidic controls and biological sensors, performed as designed, validating the concept of autonomous CubeSat laboratories. This success directly influenced subsequent missions like the O/OREOS satellite and supported the design of biological experiments for the International Space Station. The spacecraft re-entered Earth's atmosphere on 14 August 2010, concluding a trailblazing mission in astrobiology and small satellite technology.

Category:NASA spacecraft Category:CubeSats Category:2009 in spaceflight Category:Spacecraft launched in 2009